The FINANCIAL — GE Capital, Healthcare Financial Services announced today that it agented a $15 million multi-draw senior secured term loan facility to BG Medicine, Inc. The financing will help support commercialization efforts and provide additional growth capital.
BG Medicine, Inc. is a life sciences company based in Waltham, Massachusetts, that focuses on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs.
According to General Electric Company, the company, which recently launched the BGM Galectin-3TM test for use in patients with heart failure, also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders.
”Having worked with GE Capital in the past, we consider them a trusted source of financing and value the industry knowledge of their life sciences team. They were able to structure a loan facility that was well-suited to provide the capital necessary to further our product development and commercialization plans,” said Michael W. Rogers, executive vice president and chief financial officer of BG Medicine.
“We understand the challenges facing healthcare companies and our goal is to provide a reliable source of essential financing to help smart companies like BG Medicine find opportunities for growth,” said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences.